Actually, just the opposite. Taug is an investor in a company that is very experienced in testing like this.
It is always good to present accurate facts. Taug is not turning a company in infectious diseases into selling $2.50 dollar antibody tests because Taugs ex Director woke up one day and thought of a scam.
Taug is investing in a Company that is already in that space, has sales and is working with Nasdaq and NYSE companies. Nort only could this company do a nice NASDAQ listing next year but the tests they provide might be the most accurate to date and if labs implement these quick tests TAUG could get a revenue stream .
Taug does not need to be an investor. And since this Company works in the cancer field also and TAUG wants to do a trial on nausea there could be other collaborations down the pike.
Market Data 
Markets 
AI
